Drugs and Pharmaceuticals News - Page 2

Page 2 of Drugs and Pharmaceuticals News issued by the Send2Press® Newswire service.



RxQ Antioxidant Complex for Those Faced with Excessive Oxidative Stressors from Busy and Stressful Lifestyle

SAN PEDRO, Calif., July 17, 2015 (SEND2PRESS NEWSWIRE) — Schoenwetter Supplements, LLC is excited to announce the release of an advanced concept formulation of antioxidants, RxQ Antioxidant Complex. Its proprietary antioxidant formula takes into consideration not only adding antioxidants that can rapidly be depleted but is mindful of the necessary other constituents that serve to help recycle some important antioxidant systems that are everywhere present in our bodies.

SAN FRANCISCO: SB277 Protest Rally and Health Freedom March

SAN FRANCISCO, Calif., July 3, 2015 (SEND2PRESS NEWSWIRE) — The Council for Vaccine Safety announced today that on Friday, July 3, Californians will rally simultaneously in cities across the state, to illuminate the truth and stand for health, safety, education, medical freedom and justice for all. Join us as we stand in sincere opposition to the unwarranted and threatening force of the government as it moves – in partnership with big pharma – to strip us of our parental, health and medical freedoms through proposed mandated healthcare legislation, such as California Senate Bill 277.

Zofran Birth Defect Cases Being Accepted by Weitz and Luxenberg

NEW YORK, N.Y., April 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., announced it is accepting cases of congenital heart defects and cleft facial abnormalities in children whose mothers took the prescription drug Zofran during pregnancy to relieve symptoms of morning sickness.

Weitz & Luxenberg’s Relkin Appointed to Xarelto MDL Leadership Team

NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) — Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs’ steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.

Paragon BioTeck to Exhibit at American Academy of Ophthalmology Annual Meeting in Chicago

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21.

Novel Protein May Hold Promise for Enhancing Artificial Tear Formulations

PLYMOUTH, Minn., Oct. 14, 2014 (SEND2PRESS NEWSWIRE) — SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.

National Law Journal Names Weitz and Luxenberg to ‘Elite Trial Lawyers’ List, Reveals 2 Keys to Firm’s $9-Billion Actos Verdict

NEW YORK, N.Y., Oct. 1, 2014 (SEND2PRESS NEWSWIRE) — Two keys that earlier this year led to a $9-billion courtroom victory by Weitz and Luxenberg, P.C., against the maker of the diabetes drug Actos, were revealed Monday when National Law Journal named the New York City-based personal injury firm to its debut list of ‘America’s Elite Trial Lawyers.’

Lakewood College announces program to allow students to graduate from the Pharmacy Technician Certificate Program debt-free

CLEVELAND, Ohio, July 1, 2014 (SEND2PRESS NEWSWIRE) — Lakewood College is pleased to announce a new payment plan option that will allow students to graduate from the Pharmacy Technician Certificate Program without going thousands of dollars into debt.

Paragon BioTeck announces FDA Approved Phenylephrine Hydrochloride Ophthalmic Solution Readily Available

PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.

Forever Young MedSpa Introduces Exclusive New Product – PRP Gold

COOPER CITY, Fla., May 19, 2014 (SEND2PRESS NEWSWIRE) — Forever Young MedSpa announces that it was recently granted a registered trademark for PRP Gold(R), its exclusive platelet rich plasma (PRP) for treating skin conditions. ‘PRP treatments have become very popular over the past few years,’ Brian Sidella, president and founder Forever Young MedSpa, says.

Weitz and Luxenberg – Jury Awards $9 Billion to Diabetic Put at Cancer Risk by Actos

NEW YORK CITY, N.Y., April 9, 2014 (SEND2PRESS NEWSWIRE) — A Louisiana jury has awarded $9 billion to a New York man who developed bladder cancer after taking Actos, Weitz and Luxenberg announced today. The verdict, issued Monday night, orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion.

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent Readily Available

PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

Paragon Puts Ilast® Center Stage

PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) — Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.

Deer Antler Spray Company Nutronics Labs Encourages Product Comparisons

CHICAGO, Ill., Nov. 6, 2013 (SEND2PRESS NEWSWIRE) — Natural supplement company Nutronics Labs released a statement today encouraging deer antler spray consumers to do thorough product research before buying health supplements online. Nutronics Labs is the leading manufacturer of deer antler spray and boasts the world’s strongest supplements available – but as the popularity of their products continues to grow, they have seen hundreds of imitation products flood the market recently.

Paragon BioTeck Signs Exclusive Distribution Agreement with Horus Pharma for Ilast

PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.

Heart Imaging Technologies Wins $2.5M NIH Grant for Clinical Trials

DURHAM, N.C., Sept. 4, 2013 (SEND2PRESS NEWSWIRE) — HeartIT, the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the NIH in order to develop the ‘Cloud Based Corelab of the Future.’

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) — Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

CMI’s Paul Gondek and Alisa Hamilton to Co-Present with Deanna Schwarz of Pfizer at 2013 PRMG Annual National Conference

ATLANTA, Ga., March 7, 2013 (SEND2PRESS NEWSWIRE) — CMI and Pfizer will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12 in National Harbor, Md.

RXCut Plus Launches New Website to Search Best Pharmacy Prices

DOVER, Pa., Feb. 28, 2013 (SEND2PRESS NEWSWIRE) — RXCut(R) Plus announced this week a new website that is designed to help people get the best prescription price available. The Centers for Medicare and Medicaid (CMS) report that in 2014, prescription drug spending is expected to grow at a rate of 10.7 percent.

Laboratory Supply Distributors Corp. Unveils New Product Catalog

MILLVILLE, N.J., Feb. 25, 2013 (SEND2PRESS NEWSWIRE) — Laboratory Supply Distributors Corp., a provider of diverse products for the chromatography, biotechnology, pharmaceutical and environmental industries, this week announced the launch of its 2013 catalog. It showcases many new products for the life science and biotechnology markets.

CMI Further Strengthens Pharmaceutical Practice with Addition of Qualitative Leader

ATLANTA, Ga., Feb. 7, 2013 (SEND2PRESS NEWSWIRE) — CMI, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research.

Paul Gondek Joins CMI’s Healthcare Solutions Practice

ATLANTA, Ga., Sept. 28, 2012 (SEND2PRESS NEWSWIRE) — Paul Gondek has joined CMI to expand the company’s Healthcare Solutions practice to support healthcare, pharmaceutical, and medical device companies. As vice president client solutions and healthcare lead, Gondek will further enhance an experienced pharmaceutical team, using advanced analytics and immersive techniques to provide strategic insights that brand teams can use.

CMI to Co-Present with Pfizer Specialty at 2012 PMRG Annual National Conference

ATLANTA, Ga., March 8, 2012 (SEND2PRESS NEWSWIRE) — CMI’s Mike Mabey, vice president, client solutions, and Jarod Ricci, senior manager, market analytics, Pfizer Specialty, will present ‘Using Information-Seeking Behavior to Drive Segment-Specific Communication Strategies’ at the 2012 PMRG (Pharmaceutical Marketing Research Group) Annual National Conference.

E’shee Clinical Esthetic Launches High-Tech Skin Serum

PHILADELPHIA, Pa., Feb. 21, 2012 (SEND2PRESS NEWSWIRE) — E’shee Clinical Esthetic announced this week a new addition to its product line of skin serums – Elixir of Life KI Therapy Serum – designed to deliver ultimate skin rejuvenation.

Need for Eye Surgery Lessened by New Corneal Wound and Healing Treatment

NEW WINDSOR, N.Y., Feb. 14, 2012 (SEND2PRESS NEWSWIRE) — Mary Davidian, M.D., of Highland Ophthalmology Associates, a leading eye surgeon in The Hudson Valley, announces offering her patients a unique corneal wound repair and healing device called ProKera(R). Today, ProKera(R) is the only medical device that can provide wound healing to patients afflicted with a damaged cornea, the outer transparent surface of the eye.

ACTT(TM) ‘Allergy Drops’ – Needle Free Allergy Treatment

AUSTIN, Texas, Feb. 8, 2012 (SEND2PRESS NEWSWIRE) — Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy as an alternative method for administering allergy treatment for pet allergy patients. An in-house pilot study is now underway, and preliminary findings are expected in the Fall of 2012.

Belvidere Pharmacy, Custom Medicine Makers, Moves to New, and Even Better, Home

HIGHLAND PARK, N.J., Feb. 1, 2012 (SEND2PRESS NEWSWIRE) — 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere’s staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists.

Reaction Biology Corporation Unveils Largest Kinase Profiling Data Set in Nature Biotechnology Publication

MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.

Reaction Biology Launches Recombinant Methyltransferase Line

MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.

Soy Labs and Missouri Plant Science Center in Governor’s Spotlight for Innovative and Economic Development

MEXICO, Mo., Sept. 20, 2011 (SEND2PRESS NEWSWIRE) — Missouri Gov. Jay Nixon, whose job-creation strategy has focused on investing in science, technology and innovation, and encouraging and incentivizing entrepreneurship, selected Soy Labs and the Missouri Plant Science Center on Friday, as the site to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act (MOSIRA) as part of the Made in Missouri Jobs Package.

E’shee Clinical Esthetic Launches White Truffle Radiance Cream – An Extraordinary Skin Anti-oxidant

PHILADELPHIA, Pa. (SEND2PRESS NEWSWIRE) — E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream – an amazingly powerful skin anti-oxidant. This supremely elegant formula combines the finest bioengineering technologies, and offers skin the most effective anti-oxidant protection and luxurious brightening action ever experienced in skincare formulation

Millennium Administrators, Inc. Has Been Selected by The City of Scranton, Pennsylvania to Provide Benefit Administration for Active Fire and Police

SCHWENKSVILLE, Pa. (SEND2PRESS NEWSWIRE) — Millennium Administrators, Inc., a benefits administrator, has signed a contract with the City of Scranton to provide benefit administration services for over 500 city employees. Millennium is providing administrative oversight for the city benefit program, including cost containment initiatives, claim audits and administrative services to enhance cost saving initiatives at the City of Scranton.

Epeius Biotechnologies’ REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.

Business & Decision and New Strategies Partner in Order to Bring Industry Leading ERP Solutions to the Pharmaceutical Industry

PHOENIX, Ariz. (SEND2PRESS NEWSWIRE) — As a part of Business & Decision’s ongoing focus in the Life Science market, we are delighted to announce a partnership with New Strategies, the creators of ‘AX for Pharma’ an industry leading Enterprise Resource Planning solution for the Pharmaceutical industry. This solution, which is based on Microsoft Dynamics AX, has been designed to address the primary business process needs of a Life Science / Pharmaceutical organization.

Hormone Therapy and Breast Cancer: Is There a Connection?

SOMERSET, N.J. (SEND2PRESS NEWSWIRE) — From the blogosphere to mainstream media, there’s been a recent-and disturbing-buzz on a connection between hormone replacement therapy and a higher risk for advanced-stage breast cancer in post-menopausal women. The recent media focus stems from a study published in the October 2010 issue of the Journal of the American Medical Association (JAMA). Practitioners from Belvidere Pharmacy and Balancing Health, both experts in women’s health, examine the issue.

Belvidere Pharmacy Earns Top Accreditation Honor, Once Again

NORTH PLAINFIELD, N.J. (SEND2PRESS NEWSWIRE) — For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board’s (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007.

Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.

CMI Qualitative Research Manager and Ethnographer Laura Winn Johnson to Present at PMRG Institute

ATLANTA, Ga. (SEND2PRESS NEWSWIRE) — CMI, a full-service marketing research company, has been chosen for the second consecutive year to present a session at The Fourth Annual Meeting of the PMRG Institute in Boston, MA on Oct. 24-26, 2010. The theme for this year’s conference is ‘Navigating Healthcare’s Shifting Currents: Essential Techniques for the Healthcare Marketing Researcher.’

To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that ‘Sea of Troubles’

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.

Reaction Biology Receives NCI Grant Award for Epigenetic Platform

MALVERN, Pa. (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.